Humacyte (HUMA) Cash from Investing Activities (2020 - 2026)
Humacyte (HUMA) reported Cash from Investing Activities of -$175000.0 for Q1 2026, up 23.25% year-over-year from -$141992.9 in Q1 2025, and down 348.72% quarter-over-quarter from -$39000.0 in Q4 2025.
Humacyte (HUMA) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has 7 years of Cash from Investing Activities data on file, last reported at -$175000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$175000.0, up 23.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$831000.0 (up 41.02% YoY), and the FY2025 annual result was -$884000.0, up 43.77% from the prior year.
- Cash from Investing Activities slipped to -$175000.0 in Q1 2026 per HUMA's latest filing, from -$39000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $5.2 million in Q4 2022 and troughed at -$1.2 million in Q1 2023.
- A 5-year average of $120058.8 and a median of -$175000.0 in 2026 frame the typical range for Cash from Investing Activities.
- On a YoY basis, Cash from Investing Activities climbed as much as 1310.45% in 2023 and fell as far as 5136.36% in 2023.
- A 5-year view of Cash from Investing Activities shows it stood at $5.2 million in 2022, then plunged by 102.88% to -$150000.0 in 2023, then surged by 58.0% to -$63000.0 in 2024, then surged by 38.1% to -$39000.0 in 2025, then plunged by 348.72% to -$175000.0 in 2026.
- Business Quant data shows HUMA's Cash from Investing Activities at -$175000.0 in Q1 2026, -$39000.0 in Q4 2025, and -$49000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 579,519.10 |
| 10 | Humacyte | 267.09 Mn | 218.55 Mn | -1.54 Mn | -175,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -175,000.00 |
| Mar 31, 2026 | -175,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Dec 31, 2025 | -39,000.00 |
| Sep 30, 2025 | -49,000.00 |
| Sep 30, 2025 | -49,000.00 |
| Jun 30, 2025 | -568,000.00 |
| Jun 30, 2025 | -568,000.00 |
| Mar 31, 2025 | -228,000.00 |
| Mar 31, 2025 | -228,000.00 |
| Dec 31, 2024 | -63,000.00 |
| Dec 31, 2024 | -63,000.00 |
| Sep 30, 2024 | -934,000.00 |
| Sep 30, 2024 | -934,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | -391,000.00 |
| Mar 31, 2024 | -391,000.00 |
| Dec 31, 2023 | -150,000.00 |
| Dec 31, 2023 | -150,000.00 |